ClinicalTrials.gg
Active, not recruitingNCT07946029Updated Nov 18, 2026

Low vs. High Dose Oral Midazolam-Ketamine for Pediatric IV Cannulation

A Phase 4 interventional study of Midazolam and ketamine in Procedural Pain and Preoperative Anxiety, sponsored by Ibrahim Elabd Hassan Mohamed. Active, not recruiting at 1 site in Egypt. Open to participants aged 2 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Ibrahim Elabd Hassan Mohamed · Phase 4, Interventional, and Supportive care

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jul 2026, registered Nov 2026).
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
2 Years to 10 Years
Sex
All
01

Study summary

Preoperative anxiety in children makes intravenous (IV) cannulation difficult and distressing. This trial compares the success rate of painless IV cannulation among four different oral premedication regimens (Midazolam alone, Ketamine alone, Low-dose combination, and High-dose combination) in pediatric patients.

Read the detailed description

This is a prospective, randomized, double-blind, controlled trial. Pediatric patients (aged 2-10 years) will be randomized into four equal groups to receive one of four oral premedications 30 minutes before IV cannulation. The primary outcome is the success of painless IV cannulation, assessed using a validated 4-point behavioral scale. Secondary outcomes include sedation depth, parental separation anxiety, fear scores, hemodynamic stability, and adverse events.

02

Conditions studied

  • Procedural Pain
  • Preoperative Anxiety

Browse trials for

03

In context

Pain, Procedural

245 studies on the registry are indexed under Pain, Procedural; 66 are open to participants now.

This study's planned enrollment of 120 is above the median of 90 across 231 interventional studies indexed under Pain, Procedural.

Browse Pain, Procedural studies →

Lead sponsor

This is the only study on the registry with Ibrahim Elabd Hassan Mohamed as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 2 and 10 years.
  • (ASA) physical status I or II.
  • Scheduled for elective surgery under general anesthesia.
  • Requiring intravenous (IV) cannulation.
  • Written provided by parent or legal guardian.

Exclusion criteria

Exclusion Criteria:

  • (ASA) physical status >= III.
  • Known allergy or to midazolam or ketamine.
  • Neurological or psychiatric disorders.
  • Chronic use of psychotropic medications.
  • Developmental delay or cognitive impairment.
  • Anticipated difficult airway.
  • Refusal of consent.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Group M (Midazolam Monotherapy

    Oral Midazolam 0.5 mg/kg (maximum 20 mg) administered 30 minutes before IV cannulation

    Drug: Midazolam

  • Active comparator
    Group K (Ketamine Monotherapy)

    Oral Ketamine 6 mg/kg administered 30 minutes before IV cannulation

    Drug: ketamine

  • Experimental
    Group MK-LD (Low-Dose Combination)

    Oral Ketamine 3 mg/kg + Midazolam 0.25 mg/kg administered 30 minutes before IV cannulation.

    Drug: Midazolam + Ketamine

  • Experimental
    Group MK-HD (High-Dose Combination)

    Oral Ketamine 6 mg/kg + Midazolam 0.5 mg/kg administered 30 minutes before IV cannulation

    Drug: Midazolam + Ketamine

Interventions

  • Oral Midazolam 0.5 mg/kg (maximum 20 mg) administered 30 minutes before IV cannulation

  • Oral Ketamine 6 mg/kg administered 30 minutes before IV cannulation

  • DrugMidazolam + Ketamine

    Drug pages: Midazolam · Ketamine

    Oral Ketamine 3 mg/kg + Midazolam 0.25 mg/kg administered 30 minutes before IV cannulation

  • DrugMidazolam + Ketamine

    Drug pages: Midazolam · Ketamine

    Oral Ketamine 6 mg/kg + Midazolam 0.5 mg/kg administered 30 minutes before IV cannulation

06

What researchers measure

Primary outcomes

  1. Success of Painless IV Cannulation

    Successful painless IV cannulation is defined as a behavioral score \<= 1 on the 4-Point Behavioral Cannulation Score. Scores range from 0 to 3 (0 = Calm/cooperative, 1 = Mild facial grimacing, 2 = Crying/withdrawal, 3 = Severe crying/resistance). Scores of 0-1 indicate success; 2-3 indicate failure. A lower score indicates a better outcome.

    Time frame: At the time of intravenous cannulation (up to 30 minutes after premedication administration)

Secondary outcomes

  1. Parental Separation Anxiety

    Assessed using the Parental Separation Anxiety Scale (PSAS). Scores range from 1 to 4 (1 = Easy separation/calm, 4 = Cries and clings to parent). A higher score indicates a worse outcome (higher anxiety)

    Time frame: At the time of separation from parents (approximately 30 minutes after premedication)

  2. sedation level

    Assessed using the Ramsay Sedation Scale. Scores range from 1 to 6 (1 = Anxious/agitated, 6 = No response to stimuli). A higher score indicates a deeper level of sedation

    Time frame: At baseline (before premedication) and at 10, 20, and 30 minutes post-premedication

  3. Anxiety level

    Assessed using the Children's Fear Scale (CFS). This is a 5-point scale consisting of five sex-neutral faces ranging from 0 (no fear/neutral) to 4 (extreme fear). A higher score indicates a worse outcome (more anxiety)

    Time frame: At the time of intravenous cannulation

  4. Heart Rate (HR)

    Heart rate measured in beats per minute (bpm). Significant deviations may represent stress or adverse drug effects.

    Time frame: Baseline (before premedication) and every 5 minutes until IV cannulation (up to 30 minutes)

  5. Mean Blood Pressure (MBP)

    Mean blood pressure measured in millimeters of mercury (mmHg). Significant deviations may represent stress or adverse drug effects.

    Time frame: Baseline (before premedication) and every 5 minutes until IV cannulation (up to 30 minutes)

  6. Oxygen Saturation (SpO2)

    Peripheral oxygen saturation measured as a percentage (%).

    Time frame: Baseline (before premedication) and every 5 minutes until IV cannulation (up to 30 minutes)

  7. Incidence of Adverse Events

    Number of participants experiencing respiratory events (hypoxemia defined as SpO2 \< 90%, apnea), cardiovascular events (bradycardia, hypotension), behavioral events (excessive agitation, paradoxical reactions), or procedure-related events (traumatic cannulation, bleeding). A higher incidence indicates a worse outcome.

    Time frame: From premedication administration up to IV cannulation (up to 30 minutes)

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jan 2027, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 18, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 31, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07946029
Lead sponsor
Ibrahim Elabd Hassan Mohamed
Responsible party
Ibrahim Elabd Hassan Mohamed (dr.ibrahim, Aswan University Hospital) — Sponsor-investigator
First posted
Nov 18, 2026
Start date
Jul 1, 2026
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Nov 18, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Midazolam · Ketamine

Start the discussion